BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15514370)

  • 1. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
    Puduvalli VK; Yung WK; Hess KR; Kuhn JG; Groves MD; Levin VA; Zwiebel J; Chang SM; Cloughesy TF; Junck L; Wen P; Lieberman F; Conrad CA; Gilbert MR; Meyers CA; Liu V; Mehta MP; Nicholas MK; Prados M;
    J Clin Oncol; 2004 Nov; 22(21):4282-9. PubMed ID: 15514370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
    J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
    Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
    Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
    J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
    Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
    Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; BĂ©langer K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
    Robins HI; Chang SM; Prados MD; Yung WK; Hess K; Schiff D; Greenberg H; Fink K; Nicolas K; Kuhn JG; Cloughesy T; Junck L; Mehta M
    Neuro Oncol; 2002 Apr; 4(2):109-14. PubMed ID: 11916502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
    J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
    Yung WK; Kyritsis AP; Gleason MJ; Levin VA
    Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
    Cheung E; Pinski J; Dorff T; Groshen S; Quinn DI; Reynolds CP; Maurer BJ; Lara PN; Tsao-Wei DD; Twardowski P; Chatta G; McNamara M; Gandara DR
    Clin Genitourin Cancer; 2009 Jan; 7(1):43-50. PubMed ID: 19213668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
    Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
    J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
    Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
    J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.